Abstract
In the era of cancer genome medicine, the role of multidisciplinary tumor boards (MTBs) has been growing and, accordingly, the assurance of the quality of MTBs is rapidly needed. Here we present the results of a prospective analysis evaluating the concordance between treatment recommendations by the MTBs and central consensus treatment recommendations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
